Another study suggests that weight-loss meds like Wegovy (NVO) and Mounjaro (LLY) can help people cut back on drinking alcohol.

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

Weight-loss drugs like Ozempic and Wegovy are gaining popularity as quick fixes for shedding pounds. Known as GLP-1 agonists, these medications work by imitating a gut hormone that reduces hunger,

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 billion proposal from the Biden administration is blessed by President-elect Donald Trump.

The Biden-Harris administration proposed a new rule on Tuesday that would expand coverage of the anti-obesity medications known as GLP-1 treatments for Medicare and Medicaid beneficiaries. Medicare is currently only allowed to cover these medications for weight loss if they are prescribed to treat a second condition as well.

While recent advances in medicine have created prescription anti-obesity GLP-1 medications — like Ozempic, Wegovy, and Mounjaro — accessibility to these drugs is limited. The average prescription costs $1,

Weight loss drugs like Wegovy, Zepbound and Ozempic would be covered by Medicare and Medicaid under a Biden administration proposal.

Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare and Medicaid under a new rule the Biden administration proposed Tuesday morning.